Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Invested Capital: 2021-2024

Historic Invested Capital for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Dec 2024 value amounting to $438.4 million.

  • Kiniksa Pharmaceuticals International's Invested Capital rose 22.51% to $535.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $535.4 million, marking a year-over-year increase of 22.51%. This contributed to the annual value of $438.4 million for FY2024, which is 0.09% down from last year.
  • Kiniksa Pharmaceuticals International's Invested Capital amounted to $438.4 million in FY2024, which was down 0.09% from $438.8 million recorded in FY2023.
  • Kiniksa Pharmaceuticals International's 5-year Invested Capital high stood at $438.8 million for FY2023, and its period low was $185.0 million during FY2021.
  • In the last 3 years, Kiniksa Pharmaceuticals International's Invested Capital had a median value of $438.4 million in 2024 and averaged $424.5 million.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Invested Capital surged by 114.09% in 2022, and later declined by 0.09% in 2024.
  • Kiniksa Pharmaceuticals International's Invested Capital (Yearly) stood at $185.0 million in 2021, then surged by 114.09% to $396.1 million in 2022, then climbed by 10.78% to $438.8 million in 2023, then fell by 0.09% to $438.4 million in 2024.